Dynamic Advisor Solutions LLC Decreases Position in Kenvue Inc. (NYSE:KVUE)

Dynamic Advisor Solutions LLC lowered its position in Kenvue Inc. (NYSE:KVUE) by 14.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,836 shares of the company’s stock after selling 9,654 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Kenvue were worth $1,361,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Mather Group LLC. increased its holdings in Kenvue by 62.0% during the 3rd quarter. Mather Group LLC. now owns 6,857 shares of the company’s stock valued at $159,000 after acquiring an additional 2,625 shares in the last quarter. City Center Advisors LLC acquired a new stake in shares of Kenvue in the third quarter valued at approximately $217,000. Azzad Asset Management Inc. ADV increased its stake in shares of Kenvue by 2.4% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 283,383 shares of the company’s stock worth $6,555,000 after purchasing an additional 6,612 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Kenvue by 45.1% during the 3rd quarter. GAMMA Investing LLC now owns 15,890 shares of the company’s stock worth $368,000 after purchasing an additional 4,938 shares during the last quarter. Finally, Czech National Bank lifted its stake in Kenvue by 6.9% in the 3rd quarter. Czech National Bank now owns 390,139 shares of the company’s stock valued at $9,024,000 after buying an additional 25,253 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $21.32 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99. The firm has a market capitalization of $40.82 billion, a price-to-earnings ratio of 27.33, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40. Kenvue Inc. has a one year low of $17.67 and a one year high of $23.55. The company has a 50 day moving average price of $22.08 and a 200 day moving average price of $20.19.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The business had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same period in the prior year, the firm posted $0.32 EPS. The business’s revenue for the quarter was down .3% on a year-over-year basis. Sell-side analysts anticipate that Kenvue Inc. will post 1.08 EPS for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.85%. This is an increase from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date was Wednesday, August 14th. Kenvue’s dividend payout ratio (DPR) is 105.13%.

Wall Street Analyst Weigh In

Several research firms have weighed in on KVUE. UBS Group raised their price target on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Citigroup dropped their price objective on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Piper Sandler upped their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. Jefferies Financial Group initiated coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target for the company. Finally, Royal Bank of Canada downgraded shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective on the stock. in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $22.10.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.